NO933806L - Optimalisert tablettformulering - Google Patents

Optimalisert tablettformulering

Info

Publication number
NO933806L
NO933806L NO933806A NO933806A NO933806L NO 933806 L NO933806 L NO 933806L NO 933806 A NO933806 A NO 933806A NO 933806 A NO933806 A NO 933806A NO 933806 L NO933806 L NO 933806L
Authority
NO
Norway
Prior art keywords
tablet formulation
optimized
optimized tablet
formulation
tablet
Prior art date
Application number
NO933806A
Other languages
English (en)
Inventor
Ashok V Katdare
John C Cunningham
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO933806L publication Critical patent/NO933806L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO933806A 1991-04-29 1993-10-22 Optimalisert tablettformulering NO933806L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69274791A 1991-04-29 1991-04-29

Publications (1)

Publication Number Publication Date
NO933806L true NO933806L (no) 1993-10-22

Family

ID=24781844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933806A NO933806L (no) 1991-04-29 1993-10-22 Optimalisert tablettformulering

Country Status (15)

Country Link
EP (1) EP0511767A1 (no)
JP (1) JPH06157309A (no)
KR (1) KR920019340A (no)
CN (1) CN1066184A (no)
AU (1) AU1522992A (no)
CA (1) CA2067307A1 (no)
CZ (1) CZ227093A3 (no)
IE (1) IE921384A1 (no)
IL (1) IL101679A0 (no)
MX (1) MX9201969A (no)
NO (1) NO933806L (no)
NZ (1) NZ242486A (no)
SK (1) SK117793A3 (no)
WO (1) WO1992019228A1 (no)
ZA (1) ZA923068B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
ATE199495T1 (de) * 1994-12-14 2001-03-15 Enbalt Trading Ltd Pharmazeutische zubereitung zur direktverpressung
WO1997049392A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
CN1158075C (zh) * 1998-12-01 2004-07-21 诺沃挪第克公司 新药物组合物及其制备方法
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2004291149C1 (en) 2003-11-17 2021-01-21 Biomarin Pharmaceutical Inc. Methods and Compositions for the Treatment of Metabolic Disorders
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
US20090215756A1 (en) * 2005-05-18 2009-08-27 Combino Pharm, S.L. Formulations containing losartan and/or its salts
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CN105395509A (zh) * 2015-12-16 2016-03-16 宁波美诺华天康药业有限公司 一种氯沙坦钾片的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670251A (en) * 1984-05-30 1987-06-02 Igene Biotechnology, Inc. Microcrystalline tableting excipient derived from whey
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles

Also Published As

Publication number Publication date
AU1522992A (en) 1992-11-05
ZA923068B (en) 1992-12-30
KR920019340A (ko) 1992-11-19
WO1992019228A1 (en) 1992-11-12
CN1066184A (zh) 1992-11-18
CZ227093A3 (en) 1994-03-16
JPH06157309A (ja) 1994-06-03
NZ242486A (en) 1993-12-23
CA2067307A1 (en) 1992-10-30
IL101679A0 (en) 1992-12-30
EP0511767A1 (en) 1992-11-04
IE921384A1 (en) 1992-11-04
SK117793A3 (en) 1994-05-11
MX9201969A (es) 1992-11-01

Similar Documents

Publication Publication Date Title
FI934914A (fi) Farmaceutiska formuleringar
FI921060A (fi) Farmaceutiska aerosolformuleringar
FI922958A (fi) Farmaceutisk sammansaettning
FI922252A (fi) Farmaceutisk sammansaettning
FI922316A (fi) Farmaceutisk sammansaettning
FI923581A (fi) Farmaceutisk kombinationsformation
DK0616523T3 (da) Lægemidler
NO933806L (no) Optimalisert tablettformulering
NO932360D0 (no) Tablett-dispenser
NO923859D0 (no) Medikament
BR9207062A (pt) Formulação em comprimido
MX9200622A (es) Composicion farmaceutica
DE69226352D1 (de) Gehilfe
FI923401A (fi) Smaeltsystem foer koppar
ATA11391A (de) Beschlag
FI934710A0 (fi) 4-aryl-3-(heteroarylureido)kinolinderivat
MX9204183A (es) Formulacion de prostagladina e1
DK0511991T3 (da) Farmaceutisk formulering
ATA39792A (de) Maehwerk
DK138592D0 (da) Tabletter
FI925259A0 (fi) Kemiskt foerfarande
NO305649B1 (no) Silot°mmeanordning
DE69208842T2 (de) Tabletten mit verzögerter Freisetzung
BR9104215A (pt) Conjunto sub-solador multiplo
SE9201088D0 (sv) Tablettdispenser